Article
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
British journal of cancer - 1 Aug 2024
Roa Paola, Foglizzo Valentina, Harada Guilherme, Repetto Matteo, Kulick Amanda, de Stanchina Elisa, de Marchena Michelle, Auwardt Supipi, Sayed Ahmed Shaza, Bremer Nicole Virginia, Yang Soo-Ryum, Feng Yangbo, Zhou Chao, Kong Norman, Liang Ruixia, Xu Haipeng, Zhang Bin, Bardelli Alberto, Toska Eneda, Ventura Andrea, Drilon Alexander, Cocco Emiliano
Abstract excerpt
BACKGROUND: While NTRK fusion-positive cancers can be exquisitely sensitive to first-generation TRK inhibitors, resistance inevitably occurs, mediated in many cases by acquired NTRK mutations. Next-generation inhibitors (e.g., selitrectinib, repotrectinib) maintain activity against these TRK mutant tumors; however, there are no next-generation TRK inhibitors approved by the FDA and select trials have stopped...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.